期刊文献+

内源性尿嘧啶类物质比值在5-氟尿嘧啶化疗中毒性预测价值的临床研究 被引量:3

The Predictable Role of Endogenous Uracil Derivatives Ratio in 5-Fu Chemotherapy Toxicity
下载PDF
导出
摘要 目的:评价内源性二氢尿嘧啶(UH2)与尿嘧啶(U)的比值(RUH2/U)5-氟尿嘧啶(5-Fu)化疗方案中与5-氟尿嘧啶血药浓度(C5Fi)、消化系统毒性级别的相关关系,为5-氟尿嘧啶化疗方案的调整及剂量个体化提供依据。方法:对20例以5-氟尿嘧啶化疗的鼻咽癌病人,化疗前测定RUH2/U,化疗中测定5-氟尿嘧啶血药浓度,化疗后评价5-氟尿嘧啶毒性并进行相关分析。结果:RUH2/U与C5Fu、5-氟尿嘧啶致腹泻、口腔粘膜毒性均具显著相关性。结论:RUH2/U值大小可作为评价5-氟尿嘧啶临床用药的依据应用于疗效及毒性的预测。 OBJECTIVE: To investigate the relationship between the UH_2-U ratio,5- Fu concentration and toxicity in 20 nasopharynx patients and to discover if the UH_2-U ratio could be used as an indication to adjust the dose of 5Fu or to change the therapy regimen. METHODS: The plasma samples from 20 nasopharynx patients were collected, Endogenous uracil and dihydrouracil were assayed by HPLC as previous reported. The concentration of 5-Fu was determined during the chemotherapy and its toxicity was evaluated after the therapy. The correlation between them were studied. RESULTS:The result showed that the endogenous UH_2-U ratio were correlated to the concentration of 5-Fu and the toxicity induced by the 5-Fu. CONCLUSIONS: The result indicated the UH_2-U ratio can be used to predicate the toxicity of 5-Fu and to adjust the dose of 5-Fu before the treatment.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2002年第1期19-21,共3页 The Chinese Journal of Clinical Pharmacology
基金 广东省重点科技攻关项目(No:98-278-32)
关键词 尿嘧啶 二氢尿嘧啶 二氢嘧啶脱氢酶 毒性级别 5-氟尿嘧啶 uracil dihydrouracil dihydropyrimidine dehydrogenase degree of the toxicity
  • 相关文献

参考文献1

二级参考文献8

  • 1[1]Brohee D. 5-Fluorouracil and folinic acid in the treatment of advanced colorectal cancer. An updated meta-analysis. Med Set Res, 1994;22:383~384.
  • 2[2]Gamelin E ,Boisdron C, Guerin V, et al. Relationship between 5-fluorouracil dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer, 1996;77:44 1~451.
  • 3[3]Milano G,Roman P. Does versus pharmacokinatics for predicting tolerance to 5-day continous infusion of 5-Fu. Int J Cancer, 1988;41:537~541.
  • 4[4]Thyss A ,Milano G. Clinical pharmacokinetic study of the 5-Fu in continuous 5-day infusion for head and neck cancer .Cancer Chemother Pharmacol, 1986;16:64~66.
  • 5[5]Trump D, Egorin M. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole, Cancer, 1996; 77:471-475.
  • 6[6]Etienne M,Lagrange L,Dassonvile O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients.J Clin Oncol, 1994; 12:2248~2253.
  • 7[7]Gamelin E,Boisdron C.Correlation between uracil and dihydrouracil plasma ratio,fluorouracil pharmacokinetic parameter and tolerance in patient with coloretal cancer:A potiential interest for prediciting 5-Fu toxicity and determining optimal 5-Fu dosage. J Clinal Oncol, 1999;17:1105~1110.
  • 8[8]Garnelin E ,Boisdron C, Guerin V, et al. A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites.J Liq Chrom and Rel Technol, 1997; 19:3155~3172.

共引文献3

同被引文献23

  • 1[1]van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil[J]. Eur J Cancer, 2004, 40(7):939-950.
  • 2[2]Hooiveld EA, van Kuilenburg AB, Haanen JB, et al. Severe toxicity after treatment with capecitabine and tluorouracil due to partial dihydropyrimidine dehydrogenase deficiency[J]. Ned Tijdschr Geneeskd, 2004, 148(13):626-628.
  • 3[3]Ahmed FY, Johnston S J, Cassidy J, et al. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors[J]. J Clin Oncol, 1999, 17(8): 2439-2445.
  • 4[4]Ciccolini J, Mercier C, Blachon MF, et al. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity [J]. J Clin Pharm Ther, 2004, 29(4):307-315.
  • 5[5]Gamelin E, Boisdron CM, Guerin MV, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil pharmacokinetic parameter, and tolerance in patients with advanced coloretal cancer: A potential interest for predicting 5-Fu toxicity and determining optimal 5-Fu dosage [J]. J Clin Oncol, 1999, 17(4):1105-1110.
  • 6[6]朱光宣.临床药理[M].天津:天津科学技术出版社,1987:260.
  • 7[8]Lin JC, Jan JS, Hsu CY, et al. High rate of clinical complete response to weekly outpatient neoadjuvant chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin[J]. Cancer, 1999, 85(7):1430-1438.
  • 8[1]Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil [J]. Clin Cancer Res,1999,5(8): 2006-2011.
  • 9[2]van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD)deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene [J].Clin Cancer Res, 2000, 6(12): 4705 -4712.
  • 10[3]Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU) -related toxicity compared with controls [J]. Clin Cancer Res, 2001, 7(9):2832 - 2839.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部